Research backed by Brazil’s Sao Paulo Research Foundation found overweight teenagers face the same increased risk of developing heart disorders as their obese counterparts—a conclusion that contradicts the popular idea that the heavier a person is, the higher their CV risk.
Type 2 diabetes patients who undergo gastric bypass surgery as teenagers are more likely to achieve remission of their diabetes and hypertension in adulthood than adults who attempt the same procedure years later, according to a study funded by the National Institutes of Health.
More than one-third of statin patients still fail to reach healthy LDL-cholesterol levels a year and a half after initiating treatment, leaving them vulnerable to adverse CV events and thousands of dollars in medical bills, according to a report in the Journal of Managed Care & Specialty Pharmacy.
The FDA has tied sodium-glucose cotransporter-2 inhibitors to 55 cases of a life-threatening form of gangrene in the past six years, according to a May 7 report in the Annals of Internal Medicine.
Diabetic ketoacidosis is more prevalent in the U.S. than it is in Canada, according to a joint analysis from Harvard Medical School, the Cambridge Health Alliance, City University of New York and the University of Manitoba.
Researchers at the University of Georgia have uncovered 27 new metabolites associated with arterial stiffness, according to work published in the American Journal of Hypertension.
Intensive therapy to keep blood pressure (BP) levels below 130/80 mmHg helped lower the risk for heart attacks, strokes and other CV complications in patients with concomitant type 2 diabetes and hypertension, researchers have found.
The FDA has expanded Praluent’s (alirocumab) regulatory approval to reflect the reduced risk of heart attack, stroke and unstable angina evidenced in 2018’s ODYSSEY OUTCOMES trial—a move announced the same day drugmaker Sanofi released its first-quarter earnings, which were lower than expected.
The popular diabetes drug metformin reversed left ventricular hypertrophy (LVH) in a randomized trial of patients with coronary artery disease but without diabetes, suggesting a potential new use for the medication.
The FDA has cleared Gelesis100 hydrogel capsules to be used as a weight management aid alongside diet and exercise in adults with body mass indexes (BMIs) ranging from 25 to 40, according to an April 14 press release from the product’s manufacturer.
